Dermapharm off to an excellent start to financial year 2022

Grünwald, July 30, 2022 - Today, Dermapharm Holding SE ("Dermapharm"), a fast-growing manufacturer of branded pharmaceuticals, acting via its wholly owned subsidiary Dermapharm AG, submitted a binding offer to acquire 100% of the shares in Apharma TopCo SAS, the holding company of Arkopharma Group ("Arkopharma"), market leader in natural OTC products and food supplements in France.

Grünwald, 1 June 2022 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2022 Annual General Meeting. 80.43% of the share capital was in attendance at the virtual Annual General Meeting. The majority of shareholders approved the management's proposals under every agenda item.

Grünwald, 18 May 2022 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, increased its consolidated revenue by 9.1% to EUR 231.6 million in the first quarter of financial year 2022 (prior-year period: EUR 212.2 million).